Cargando…
Towards a new tuberculosis drug: pyridomycin – nature's isoniazid
Tuberculosis, a global threat to public health, is becoming untreatable due to widespread drug resistance to frontline drugs such as the InhA-inhibitor isoniazid. Historically, by inhibiting highly vulnerable targets, natural products have been an important source of antibiotics including potent ant...
Autores principales: | Hartkoorn, Ruben C, Sala, Claudia, Neres, João, Pojer, Florence, Magnet, Sophie, Mukherjee, Raju, Uplekar, Swapna, Boy-Röttger, Stefanie, Altmann, Karl-Heinz, Cole, Stewart T |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
WILEY-VCH Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491834/ https://www.ncbi.nlm.nih.gov/pubmed/22987724 http://dx.doi.org/10.1002/emmm.201201689 |
Ejemplares similares
-
Virulence Regulator EspR of Mycobacterium tuberculosis Is a Nucleoid-Associated Protein
por: Blasco, Benjamin, et al.
Publicado: (2012) -
High-resolution transcriptome and genome-wide dynamics of RNA polymerase and NusA in Mycobacterium tuberculosis
por: Uplekar, Swapna, et al.
Publicado: (2013) -
Genomic and transcriptomic analysis of the streptomycin-dependent Mycobacterium tuberculosis strain 18b
por: Benjak, Andrej, et al.
Publicado: (2016) -
Towards a new combination therapy for tuberculosis with next generation benzothiazinones
por: Makarov, Vadim, et al.
Publicado: (2014) -
A Point Mutation in cycA Partially Contributes to the D-cycloserine Resistance Trait of Mycobacterium bovis BCG Vaccine Strains
por: Chen, Jeffrey M., et al.
Publicado: (2012)